About: Real-Time Quantitative Fluorescent Reverse Transcriptase-PCR for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus RNA

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Real-Time Quantitative Fluorescent Reverse Transcriptase-PCR for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus RNA Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Real-Time Quantitative Fluorescent Reverse Transcriptase-PCR for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus RNA
Creator	Wang, Jian Lin, Lin Chen, Weijun Mu, Feng Yang, Ling Wen, Jie Xu, Zuyuan Meng, Shufang Fang, Jianqiu He, Bo Huang, Shengyong Mu, Jingsong Gan, Haixue
Source	Medline; PMC
abstract	Aim: SARS-associated coronavirus (SARS-CoV) has been confirmed as the pathogen for severe acute respiratory syndrome (SARS). The aim of our study was to construct a sensitive and specific real-time quantitative fluorescent (QF) reverse transcriptase (RT)-PCR method for the detection of SARS-CoV RNA. Methods: Stored blood specimens from 44 patients with confirmed SARS were used along with blood samples from two sets of controls, 30 healthy volunteers who had no contact with SARS patients, and 30 healthy doctors and nurses who had contact with SARS patients but were without symptoms of SARS. Two pairs of primers were synthesized by the Shanghai Sangon Company according to SARS-CoV BJ01 strain sequence (AY278488), and then a pair of primers were designed and compared with a pair of primers published by WHO. Results: Using serial dilutions of SARS-CoV, the 44 blood samples from SARS patients specimens were tested. Using a 0.01% dilution of SARS-CoV, all 44 clinical samples tested positive in our assay. In comparison, using a 0.1% dilution of SARS-CoV, 26 of the 44 samples tested positive using the WHO primers. In the QF-RT-PCR assay, there was a linear amplification from 100 copies to 10(8) copies of the control RNA per RT-PCR and at least 10 copies, and sometimes even 1 copy, of target RNA tested positive in our assay. Conclusion: The primer we developed is sufficiently sensitive and specific to diagnose symptomatic SARS-CoV infections and for monitoring virus load.
has issue date	2012-12-01(xsd:dateTime)
bibo:doi	10.1007/bf03260067
bibo:pmid	15887978
has license	no-cc
sha1sum (hex)	9110b6136dafccd5110c9d56f30e97b5356afa7b
schema:url	https://doi.org/10.1007/bf03260067
resource representing a document's title	Real-Time Quantitative Fluorescent Reverse Transcriptase-PCR for Detection of Severe Acute Respiratory Syndrome-Associated Coronavirus RNA
has PubMed Central identifier	PMC7100218
has PubMed identifier	15887978
schema:publication	Mol Diagn
resource representing a document's body	covid:9110b6136dafccd5110c9d56f30e97b5356afa7b#body_text
is schema:about of	named entity 'sensitive' named entity 'SARS-CoV' named entity 'severe' named entity 'RT-PCR' named entity 'blood' named entity 'Acute' named entity 'Coronavirus' named entity 'OUR' named entity '100' named entity 'LINEAR AMPLIFICATION' named entity 'COMPARED' named entity 'STORED' named entity 'RNA' named entity 'PAIRS' named entity 'STRAIN' named entity 'SYNDROME' named entity 'STUDY' named entity 'INFECTIONS' named entity 'TARGET' named entity 'ACCORDING' named entity 'DETECTION' named entity 'USING' named entity 'COPIES' named entity 'HEALTHY VOLUNTEERS' named entity 'SYMPTOMATIC' named entity 'PRIMERS' named entity 'SEVERE' named entity 'SARS-COV' named entity 'REVERSE TRANSCRIPTASE' named entity 'WAS A' named entity 'BLOOD' named entity 'CONFIRMED' named entity 'REAL-TIME' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'QUANTITATIVE' named entity 'ASSOCIATED' named entity 'SARS' named entity 'TESTED' named entity 'DILUTION' named entity 'REAL-TIME' named entity 'SPECIMENS' named entity 'PATIENTS' named entity 'PUBLISHED' named entity 'RT-PCR ASSAY' named entity 'ABSTRACT' named entity 'COMPANY' named entity 'DOCTORS' named entity 'CONTROL' named entity 'FLUORESCENT' named entity 'NURSES' named entity 'SENSITIVE' named entity 'QUANTITATIVE' named entity 'COMPARISON' named entity 'SEQUENCE' named entity 'HEALTHY' named entity 'CONTACT WITH' named entity 'BUT' named entity 'ACUTE' named entity 'ASSAY' named entity 'CLINICAL' named entity 'PATHOGEN' named entity 'METHODS' named entity 'SAMPLES' named entity 'SYNTHESIZED' named entity 'SPECIFIC' named entity 'PAIR' named entity 'AIM' named entity 'PRIMER' named entity '0.1'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software